1
|
Subramaniam S, Joyce P, Prestidge CA. The biomolecule corona mediates pulmonary delivery of nanomedicine. Eur J Pharm Biopharm 2024; 202:114420. [PMID: 39038525 DOI: 10.1016/j.ejpb.2024.114420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2024] [Revised: 06/12/2024] [Accepted: 07/16/2024] [Indexed: 07/24/2024]
Abstract
Pulmonary delivery of therapeutics (e.g., biologics, antibiotics, and chemotherapies) encapsulated in nanoparticles is desirable for the ability to provide a localised treatment, bypassing the harsh gastrointestinal environment. However, limited understanding of the biological fate of nanoparticles upon administration to the lungs hinders translation of pre-clinical investigations into viable therapies. A key knowledge gap is the impact of the pulmonary biomolecular corona on the functionality of nanoparticles. In this review, opportunities and challenges associated with pulmonary nanoparticle delivery are elucidated, highlighting the impact of the pulmonary biomolecular corona on immune recognition and nanoparticle internalisation in target cells. Recent investigations detailing the influence of proteins, lipids and mucin derived from pulmonary surfactants on nanoparticle behaviour are detailed. In addition, latest approaches in modulating plasma protein corona upon systemic delivery for biodistribution to the lungs are also discussed. Key examples of reengineering nanoparticle structure to mediate formation of biomolecule corona are provided. This review aims to provide a comprehensive understanding on biomolecular corona of nanoparticles for pulmonary delivery, while accentuating their significance for successful translation of newly investigated therapeutics.
Collapse
Affiliation(s)
- Santhni Subramaniam
- University of South Australia, UniSA Clinical and Health Sciences, SA 5000, Australia
| | - Paul Joyce
- University of South Australia, UniSA Clinical and Health Sciences, SA 5000, Australia
| | - Clive A Prestidge
- University of South Australia, UniSA Clinical and Health Sciences, SA 5000, Australia.
| |
Collapse
|
2
|
Sodipo BK, Kasim Mohammed Z. Advances in biodistribution of gold nanoparticles: the influence of size, surface charge, and route of administration. Biomed Mater 2024; 19:042010. [PMID: 38838693 DOI: 10.1088/1748-605x/ad5484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2024] [Accepted: 06/05/2024] [Indexed: 06/07/2024]
Abstract
To improve the translational and clinical applications of gold nanoparticles (GNPs) in medicine there is a need for better understanding of physicochemical properties of the nanoparticles in relation to the systemic parameters andin-vivoperformance. This review presents the influence of physicochemical properties (surface charges and size) and route of administration on the biodistribution of GNPs. The role of protein corona (PC) (a unique biological identifier) as a barrier to biodistribution of GNPs, and the advances in engineered GNPs towards improving biodistribution are presented. Proteins can easily adsorb on charged (anionic and cationic) functionalized GNPs in circulation and shape the dynamics of their biodistribution. Non-ionic coatings such as PEG experience accelerated blood clearance (ABC) due to immunogenic response. While zwitterionic coatings provide stealth effects to formation of PC on the GNPs. GNPs with sizes less than 50 nm were found to circulate to several organs while the route of administration of the GNPs determines the serum protein that adsorbs on the nanoparticles.
Collapse
Affiliation(s)
- Bashiru K Sodipo
- Department of Physics, Kaduna State University, Kaduna, Nigeria
- Sabanci University Nanotechnology Research and Application Center (SUNUM), Istanbul, Turkey
| | | |
Collapse
|
3
|
Glencross DA, Ho TR, Camiña N, Hawrylowicz CM, Pfeffer PE. Air pollution and its effects on the immune system. Free Radic Biol Med 2020; 151:56-68. [PMID: 32007522 DOI: 10.1016/j.freeradbiomed.2020.01.179] [Citation(s) in RCA: 269] [Impact Index Per Article: 67.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Revised: 01/21/2020] [Accepted: 01/22/2020] [Indexed: 12/22/2022]
Abstract
A well-functioning immune system is vital for a healthy body. Inadequate and excessive immune responses underlie diverse pathologies such as serious infections, metastatic malignancies and auto-immune conditions. Therefore, understanding the effects of ambient pollutants on the immune system is vital to understanding how pollution causes disease, and how that pathology could be abrogated. The immune system itself consists of multiple types of immune cell that act together to generate (or fail to generate) immune responses and in this article we review evidence of how air pollutants can affect different immune cell types such as particle-clearing macrophages, inflammatory neutrophils, dendritic cells that orchestrate adaptive immune responses and lymphocytes that enact those responses. Common themes that emerge are of the capacity of air pollutants to stimulate pro-inflammatory immune responses across multiple classes of immune cell. Air pollution can enhance T helper lymphocyte type 2 (Th2) and T helper lymphocyte type 17 (Th17) adaptive immune responses, as seen in allergy and asthma, and dysregulate anti-viral immune responses. The clinical effects of air pollution, in particular the known association between elevated ambient pollution and exacerbations of asthma and chronic obstructive pulmonary disease (COPD), are consistent with these identified immunological mechanisms. Further to this, as inhaled air pollution deposits primarily on the respiratory mucosa this review focuses on mechanisms of respiratory disease. However, as discussed in the article, air pollution also affects the wider immune system for example in the neonate and gastrointestinal tract. Whilst the many identified actions of air pollution on the immune system are notably diverse, immunological research does suggest potential strategies to ameliorate such effects, for example with vitamin D supplementation. An in-depth understanding of the immunological effects of ambient pollutants should hopefully yield new ideas on how to reduce the adverse health effects of air pollution.
Collapse
Affiliation(s)
- Drew A Glencross
- Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, Guy's Hospital, London, SE1 9RT, UK; MRC Centre for Environment and Health, King's College London, Franklin Wilkins Building, London, SE1 9NH, UK
| | - Tzer-Ren Ho
- Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, Guy's Hospital, London, SE1 9RT, UK; MRC Centre for Environment and Health, King's College London, Franklin Wilkins Building, London, SE1 9NH, UK
| | - Nuria Camiña
- MRC Centre for Environment and Health, King's College London, Franklin Wilkins Building, London, SE1 9NH, UK
| | - Catherine M Hawrylowicz
- Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, Guy's Hospital, London, SE1 9RT, UK.
| | - Paul E Pfeffer
- Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| |
Collapse
|
4
|
Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2017. [PMID: 28647590 DOI: 10.1016/j.nano.2017.06.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Most inhaled nanomedicines in development are for the treatment of lung disease, yet little is known about their interaction with the respiratory tract lining fluids (RTLFs). Here we combined the use of nano-silica, as a protein concentrator, with label-free snapshot proteomics (LC-MS/MS; key findings confirmed by ELISA) to generate a quantitative profile of the RTLF proteome and provided insight into the evolved corona; information that may be used in future to improve drug targeting to the lungs by inhaled medicines. The asthmatic coronal proteome displayed a reduced contribution of surfactant proteins (SP-A and B) and a higher contribution of α1-antitrypsin. Pathway analysis suggested that asthmatic RTLFs may also be deficient in proteins related to metal handling (e.g. lactoferrin). This study demonstrates how the composition of the corona acquired by inhaled nanoparticles is modified in asthma and suggests depressed mucosal immunity even in mild airway disease.
Collapse
|
5
|
Dua K, Hansbro NG, Foster PS, Hansbro PM. MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases. Drug Deliv Transl Res 2016; 7:168-178. [DOI: 10.1007/s13346-016-0343-6] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
6
|
Kumar A, Bicer EM, Morgan AB, Pfeffer PE, Monopoli M, Dawson KA, Eriksson J, Edwards K, Lynham S, Arno M, Behndig AF, Blomberg A, Somers G, Hassall D, Dailey LA, Forbes B, Mudway IS. Enrichment of immunoregulatory proteins in the biomolecular corona of nanoparticles within human respiratory tract lining fluid. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2016; 12:1033-1043. [PMID: 26767511 DOI: 10.1016/j.nano.2015.12.369] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Revised: 12/04/2015] [Accepted: 12/10/2015] [Indexed: 12/19/2022]
Abstract
UNLABELLED When inhaled nanoparticles deposit in the lungs, they transit through respiratory tract lining fluid (RTLF) acquiring a biomolecular corona reflecting the interaction of the RTLF with the nanomaterial surface. Label-free snapshot proteomics was used to generate semi-quantitative profiles of corona proteins formed around silica (SiO2) and poly(vinyl) acetate (PVAc) nanoparticles in RTLF, the latter employed as an archetype drug delivery vehicle. The evolved PVAc corona was significantly enriched compared to that observed on SiO2 nanoparticles (698 vs. 429 proteins identified); however both coronas contained a substantial contribution from innate immunity proteins, including surfactant protein A, napsin A and complement (C1q and C3) proteins. Functional protein classification supports the hypothesis that corona formation in RTLF constitutes opsonisation, preparing particles for phagocytosis and clearance from the lungs. These data highlight how an understanding of the evolved corona is necessary for the design of inhaled nanomedicines with acceptable safety and tailored clearance profiles. FROM THE CLINICAL EDITOR Inhaled nanoparticles often acquire a layer of protein corona while they go through the respiratory tract. Here, the authors investigated the identity of these proteins. The proper identification would improve the understanding of the use of inhaled nanoparticles in future therapeutics.
Collapse
Affiliation(s)
- Abhinav Kumar
- Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College, LondonUK.
| | - Elif Melis Bicer
- MRC-PHE Centre for Environment and Health and NIHR-HPRU in the Health Impact of Environmental Hazards, Environmental and Analytical Research, Division, Faculty of Life Sciences and Medicine, King's College, London, UK
| | - Anna Babin Morgan
- Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College, LondonUK
| | - Paul E Pfeffer
- MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Faculty of Life Sciences and Medicine, King's College, London, UK
| | - Marco Monopoli
- Centre for BioNano Interactions, University College Dublin, Belfield, Dublin 4, Ireland
| | - Kenneth A Dawson
- Centre for BioNano Interactions, University College Dublin, Belfield, Dublin 4, Ireland
| | - Jonny Eriksson
- Department of Chemistry - BMC, Uppsala University, Sweden
| | | | - Steven Lynham
- Institute of Psychiatry, Psychology and Neuroscience, Faculty of Life Sciences and Medicine, King's College, London, UK
| | - Matthew Arno
- Genomics Centre, Faculty of Life Sciences and Medicine, King's College, London, UK
| | - Annelie F Behndig
- Department of Public Health and Clinical Medicine, Division of Medicine/Respiratory Medicine and Allergy, Umeå University, Umeå, Sweden
| | - Anders Blomberg
- Department of Public Health and Clinical Medicine, Division of Medicine/Respiratory Medicine and Allergy, Umeå University, Umeå, Sweden
| | - Graham Somers
- GSK Medicines Research Centre, Stevenage, Hertfordshire, UK
| | - Dave Hassall
- GSK Medicines Research Centre, Stevenage, Hertfordshire, UK
| | - Lea Ann Dailey
- Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College, LondonUK
| | - Ben Forbes
- Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College, LondonUK
| | - Ian S Mudway
- MRC-PHE Centre for Environment and Health and NIHR-HPRU in the Health Impact of Environmental Hazards, Environmental and Analytical Research, Division, Faculty of Life Sciences and Medicine, King's College, London, UK
| |
Collapse
|
7
|
Corbo C, Molinaro R, Parodi A, Toledano Furman NE, Salvatore F, Tasciotti E. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine (Lond) 2016; 11:81-100. [PMID: 26653875 PMCID: PMC4910943 DOI: 10.2217/nnm.15.188] [Citation(s) in RCA: 410] [Impact Index Per Article: 51.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2015] [Accepted: 10/29/2015] [Indexed: 12/17/2022] Open
Abstract
In a perfect sequence of events, nanoparticles (NPs) are injected into the bloodstream where they circulate until they reach the target tissue. The ligand on the NP surface recognizes its specific receptor expressed on the target tissue and the drug is released in a controlled manner. However, once injected in a physiological environment, NPs interact with biological components and are surrounded by a protein corona (PC). This can trigger an immune response and affect NP toxicity and targeting capabilities. In this review, we provide a survey of recent findings on the NP-PC interactions and discuss how the PC can be used to modulate both cytotoxicity and the immune response as well as to improve the efficacy of targeted delivery of nanocarriers.
Collapse
Affiliation(s)
- Claudia Corbo
- Department of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Avenue, 77030 Houston, TX, USA
- Fondazione SDN, Via Gianturco 113, 80143 Naples, Italy
| | - Roberto Molinaro
- Department of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Avenue, 77030 Houston, TX, USA
| | - Alessandro Parodi
- Department of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Avenue, 77030 Houston, TX, USA
- Fondazione SDN, Via Gianturco 113, 80143 Naples, Italy
| | - Naama E Toledano Furman
- Department of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Avenue, 77030 Houston, TX, USA
| | - Francesco Salvatore
- CEINGE, Advanced Biotechnology s.c.a.r.l., Via G. Salvatore 486, 80145 Naples, Italy
| | - Ennio Tasciotti
- Department of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Avenue, 77030 Houston, TX, USA
| |
Collapse
|
8
|
Raesch SS, Tenzer S, Storck W, Rurainski A, Selzer D, Ruge CA, Perez-Gil J, Schaefer UF, Lehr CM. Proteomic and Lipidomic Analysis of Nanoparticle Corona upon Contact with Lung Surfactant Reveals Differences in Protein, but Not Lipid Composition. ACS NANO 2015; 9:11872-85. [PMID: 26575243 DOI: 10.1021/acsnano.5b04215] [Citation(s) in RCA: 133] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
Pulmonary surfactant (PS) constitutes the first line of host defense in the deep lung. Because of its high content of phospholipids and surfactant specific proteins, the interaction of inhaled nanoparticles (NPs) with the pulmonary surfactant layer is likely to form a corona that is different to the one formed in plasma. Here we present a detailed lipidomic and proteomic analysis of NP corona formation using native porcine surfactant as a model. We analyzed the adsorbed biomolecules in the corona of three NP with different surface properties (PEG-, PLGA-, and Lipid-NP) after incubation with native porcine surfactant. Using label-free shotgun analysis for protein and LC-MS for lipid analysis, we quantitatively determined the corona composition. Our results show a conserved lipid composition in the coronas of all investigated NPs regardless of their surface properties, with only hydrophilic PEG-NPs adsorbing fewer lipids in total. In contrast, the analyzed NP displayed a marked difference in the protein corona, consisting of up to 417 different proteins. Among the proteins showing significant differences between the NP coronas, there was a striking prevalence of molecules with a notoriously high lipid and surface binding, such as, e.g., SP-A, SP-D, DMBT1. Our data indicate that the selective adsorption of proteins mediates the relatively similar lipid pattern in the coronas of different NPs. On the basis of our lipidomic and proteomic analysis, we provide a detailed set of quantitative data on the composition of the surfactant corona formed upon NP inhalation, which is unique and markedly different to the plasma corona.
Collapse
Affiliation(s)
- Simon Sebastian Raesch
- Department of Pharmacy, Saarland University , 66123 Saarbruecken, Germany
- HIPS - Helmholtz Institute for Pharmaceutical Research Saarland , Helmholtz Centre for Infection Research, 66123 Saarbruecken, Germany
| | - Stefan Tenzer
- Institute of Immunology, Mainz University , 55131 Mainz, Germany
| | - Wiebke Storck
- Institute of Immunology, Mainz University , 55131 Mainz, Germany
| | - Alexander Rurainski
- Scientific Consilience GmbH, Saarland University , 66123 Saarbruecken, Germany
| | - Dominik Selzer
- Scientific Consilience GmbH, Saarland University , 66123 Saarbruecken, Germany
| | | | - Jesus Perez-Gil
- Department of Biochemistry and Molecular Biology, Faculty of Biology, Complutense University , 28040 Madrid, Spain
| | | | - Claus-Michael Lehr
- Department of Pharmacy, Saarland University , 66123 Saarbruecken, Germany
- HIPS - Helmholtz Institute for Pharmaceutical Research Saarland , Helmholtz Centre for Infection Research, 66123 Saarbruecken, Germany
| |
Collapse
|